New stem cell filter could make transplants safer for vulnerable patients

NCT ID NCT06731036

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This expanded access program offers a special stem cell purification technique (CD34+ selection) for patients undergoing stem cell transplants. The method removes many T-cells from the donated stem cells, which lowers the risk of a serious complication called graft-versus-host disease. It is available for patients with severe combined immunodeficiency, Fanconi anemia, dyskeratosis congenita, or sickle cell disease who need a transplant.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

CD34+ cell enriched stem cell graft

What this could lead to

If successful, this could provide a safer stem cell transplant option for patients with severe immune deficiencies or sickle cell disease by reducing the risk of graft-versus-host disease.

What could go wrong

This is an expanded access program, not a formal trial, so results are not systematically collected. The procedure still carries risks like infection or graft failure, and it may not work for everyone.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SICKLE CELL DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

dyskeratosis congenita Fanconi anemia severe combined immunodeficiency sickle cell disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••